NYSEARCA:ZOM - NYSE Arca - CA98980M1095 - Common Stock - Currency: USD
0.1198
0 (-0.66%)
The current stock price of ZOM is 0.1198 USD. In the past month the price decreased by -3.7%. In the past year, price decreased by -3.78%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
ZOMEDICA CORP
100 Phoenix Drive, Suite 125
Ann Arbor MICHIGAN 48108 US
CEO: Robert Cohen
Employees: 144
Company Website: https://zomedica.com/
Investor Relations: http://investors.zomedica.com
Phone: 17343692555
The current stock price of ZOM is 0.1198 USD. The price decreased by -0.66% in the last trading session.
The exchange symbol of ZOMEDICA CORP is ZOM and it is listed on the NYSE Arca exchange.
ZOM stock is listed on the NYSE Arca exchange.
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 112.85% is expected in the next year compared to the current price of 0.1198. Check the ZOMEDICA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ZOMEDICA CORP (ZOM) has a market capitalization of 117.40M USD. This makes ZOM a Micro Cap stock.
ZOMEDICA CORP (ZOM) currently has 144 employees.
ZOMEDICA CORP (ZOM) has a support level at 0.12 and a resistance level at 0.12. Check the full technical report for a detailed analysis of ZOM support and resistance levels.
The Revenue of ZOMEDICA CORP (ZOM) is expected to grow by 10.67% in the next year. Check the estimates tab for more information on the ZOM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZOM does not pay a dividend.
ZOMEDICA CORP (ZOM) will report earnings on 2025-03-04, after the market close.
ZOMEDICA CORP (ZOM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
The outstanding short interest for ZOMEDICA CORP (ZOM) is 4.64% of its float. Check the ownership tab for more information on the ZOM short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ZOM. No worries on liquidiy or solvency for ZOM as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.05% | ||
ROE | -30.66% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to ZOM. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM